Turns out a new HIV drug can reduce the viral replication and increase immune cells in individuals with advanced drug-resistant HIV infection. For some individuals with HIV existing drug therapies fail to suppress the virus leading to drug resistance and worsening disease. While several HIV drugs target the virus effectively there has not been a new class of HIV drugs approved to combat the disease in a decade. During the study patients received a dose of ibalizumab which is delivered intravenously in addition to their failing regimen for one week. After that period they received ibalizumab in combination with optimized
